Program Code: SCF-DBI-PICU-PHARM-0001**
Operational Window: PICU Admission → Recovery → Discharge → Longitudinal Follow-Up
Primary Objective: Optimize pharmacologic interventions while preserving neurodevelopment, immune regulation, endothelial integrity, metabolic adaptation, functional recovery, and long-term pediatric resilience.
SECTION 13.1
CLINICAL POSITIONING
Traditional PICU Pharmacology Model
Focuses on:
- Drug efficacy
- Dose optimization
- Toxicity prevention
- Therapeutic monitoring
SCF-DBI Pharmacology Model
All pharmacologic interventions are evaluated for effects upon:
Neurocognitive Development
Immune Regulation
Endothelial Integrity
Metabolic Adaptation
Recovery Capacity
Functional Outcomes
Educational Reintegration
Core Principle
The optimal pediatric therapy achieves clinical objectives while minimizing disruption of biologic intelligence and developmental trajectories.
SECTION 13.2
RHENOVA PRECISION PEDIATRIC PHARMACOTHERAPY PLATFORM
Strategic Objective
Integrate pharmacotherapy directly into biologic intelligence surveillance.
Pharmacology Domains
Domain 1
Developmental Pharmacology
Domain 2
Neuropharmacology
Domain 3
Immunopharmacology
Domain 4
Endothelial Pharmacology
Domain 5
Recovery Pharmacology
Domain 6
Functional Outcome Pharmacology
Operational Goal
Match treatment intensity to adaptive reserve and recovery potential.
SECTION 13.3
PHARMACOLOGY INTELLIGENCE SURVEILLANCE SYSTEM (PISS)
Purpose
Quantify biologic impact of medication exposure.
Domain A
Drug Exposure Burden
Domain B
Neurodevelopmental Burden
Domain C
Immune Impact Burden
Domain D
Endothelial Impact Burden
Domain E
Recovery Impact Burden
Output
Pharmacologic Adaptation Index (PAI)
SECTION 13.4
ANTIMICROBIAL STEWARDSHIP SOP
Clinical Positioning
Antimicrobials are viewed as:
Necessary but Potentially Disruptive Recovery Tools
Objectives
Appropriate initiation
Appropriate spectrum
Appropriate duration
Appropriate de-escalation
Preservation of immune adaptation
Initiation Criteria
Evaluate:
Clinical presentation
Infection probability
Culture data
ANMS
STRI
Daily Stewardship Review
Assess:
Culture results
Clinical response
Biomarker trends
Recovery trajectory
De-escalation Criteria
Source control achieved
Clinical improvement
Biomarker improvement
Stable recovery trajectory
SECTION 13.5
IMMUNOMODULATORY THERAPY FRAMEWORK
Clinical Applications
MIS-C
Hyperinflammatory syndromes
Severe autoimmune disease
Transplant immunomodulation
Neuroimmune disorders
Objectives
Restore:
Immune regulation
Self-tolerance
Recovery capacity
Endothelial stability
Monitoring Variables
STRI
ANMS
Ferritin
CRP
Cytokine burden
SECTION 13.6
SEDATION INTELLIGENCE PROGRAM
Strategic Position
Sedation affects:
Cognitive recovery
Delirium risk
Neuroplasticity
Sleep architecture
Functional rehabilitation
Sedation Goals
Comfort
Safety
Recovery preservation
Monitoring Domains
Sedation Adequacy
Delirium Risk
Sleep Integrity
Cognitive Recovery
Output
Sedation Intelligence Score (SIS)
SIS CLASSIFICATION
Green
Appropriate adaptation
Yellow
Monitor closely
Orange
Recovery burden emerging
Red
High neurodevelopmental burden